Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 2/20 | 0.38 |
| ▸ | MMP9 | P14780 | 2/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | TEK | Q02763 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.35 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4208549 | 1.00 | CA1 (0.39) | CA1CA2CA4CA9MMP2 | |
| SCHEMBL1843133 | 1.00 | CA1 (0.39) | CA1CA2CA4CA9MMP2 | |
| SCHEMBL4927004 | 0.90 | MMP2 (0.45) | MMP2MMP9KDRKDM4EUSP2 | |
| SCHEMBL1844730 | 0.90 | MMP2 (0.45) | MMP2MMP9KDRKDM4EUSP2 | |
| SCHEMBL4932775 | 0.90 | MMP2 (0.45) | MMP2MMP9KDRKDM4EUSP2 | |
| SCHEMBL4932227 | 0.90 | MMP2 (0.45) | MMP2MMP9KDRKDM4EUSP2 | |
| SCHEMBL4922678 | 0.90 | MMP2 (0.45) | MMP2MMP9KDRKDM4EUSP2 | |
| SCHEMBL4212827 | 0.90 | CA1 (0.41) | CA1CA2CA4CA9MMP2 | |
| SCHEMBL4212826 | 0.90 | CA1 (0.41) | CA1CA2CA4CA9MMP2 | |
| SCHEMBL1841166 | 0.90 | CA1 (0.41) | CA1CA2CA4CA9MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1856063-B1 | 5-PHENYL-PENTANOIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS FOR THE TREATMENT OF ASTHMA AND OTHER DISEASES | RANBAXY LAB LTD (IN) | 2012-01-25 | — | — | EP | claimed |
| US-20080194565-A1 | 5-Phenyl-Pentanoic Acid Derivatives as Matrix Metalloproteinase Inhibitors for the Treatment of Asthma and Other Diseases | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2008-08-14 | — | — | US | claimed |
| US-8710261-B2 | 5-phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other diseases | RANBAXY LABORATORIES LIMITED (IN) | 2014-04-29 | — | — | US | disclosed |
| EP-1856063-B1 | 5-PHENYL-PENTANOIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS FOR THE TREATMENT OF ASTHMA AND OTHER DISEASES | RANBAXY LAB LTD (IN) | 2012-01-25 | — | — | EP | disclosed |
| US-20080194565-A1 | 5-Phenyl-Pentanoic Acid Derivatives as Matrix Metalloproteinase Inhibitors for the Treatment of Asthma and Other Diseases | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2008-08-14 | — | — | US | disclosed |
| EP-1856063-A1 | 5-PHENYL-PENTANOIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS FOR THE TREATMENT OF ASTHMA AND OTHER DISEASES | Ranbaxy Laboratories Limited (IN) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006090235-A1 | 5-PHENYL-PENTANOIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS FOR THE TREATMENT OF ASTHMA AND OTHER DISEASES | RANBAXY LABORATORIES LIMITED (IN) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194565-A1 | 5-Phenyl-Pentanoic Acid Derivatives as Matrix Metalloproteinase Inhibitors for the Treatment of Asthma and Other Diseases | F2RL3, ACOX3, LPAR5 | CA1 2298/4885CA2 1072/4885CA4 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.